SeaCrest Wealth Management LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,014 shares of the medical device company’s stock after selling 96 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in DexCom were worth $411,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in DXCM. Alps Advisors Inc. boosted its position in shares of DexCom by 0.8% during the 1st quarter. Alps Advisors Inc. now owns 3,782 shares of the medical device company’s stock valued at $1,018,000 after acquiring an additional 31 shares during the last quarter. Laurel Wealth Advisors LLC raised its stake in DexCom by 15.0% in the first quarter. Laurel Wealth Advisors LLC now owns 246 shares of the medical device company’s stock valued at $66,000 after purchasing an additional 32 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in DexCom by 0.8% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,975 shares of the medical device company’s stock valued at $1,339,000 after purchasing an additional 39 shares during the last quarter. Lindbrook Capital LLC grew its stake in DexCom by 42.6% in the 1st quarter. Lindbrook Capital LLC now owns 134 shares of the medical device company’s stock worth $36,000 after buying an additional 40 shares in the last quarter. Finally, Perennial Investment Advisors LLC increased its holdings in shares of DexCom by 5.9% in the 2nd quarter. Perennial Investment Advisors LLC now owns 847 shares of the medical device company’s stock worth $343,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.
In other news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $344.63, for a total transaction of $2,067,780.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick Michael Murphy sold 500 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $404.05, for a total transaction of $202,025.00. The disclosure for this sale can be found here. Insiders sold 63,293 shares of company stock worth $24,266,963 over the last three months. Insiders own 0.69% of the company’s stock.
NASDAQ DXCM opened at $417.79 on Wednesday. DexCom, Inc. has a 12 month low of $138.28 and a 12 month high of $446.50. The company has a current ratio of 5.82, a quick ratio of 5.41 and a debt-to-equity ratio of 1.23. The stock’s fifty day moving average price is $407.68 and its 200-day moving average price is $322.24. The stock has a market cap of $39.10 billion, a P/E ratio of 262.76 and a beta of 0.79.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, July 28th. The medical device company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.51. DexCom had a net margin of 9.24% and a return on equity of 26.44%. The firm had revenue of $451.80 million for the quarter, compared to analysts’ expectations of $415.21 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The business’s revenue for the quarter was up 34.3% on a year-over-year basis. As a group, analysts forecast that DexCom, Inc. will post 2.27 earnings per share for the current fiscal year.
Several brokerages recently issued reports on DXCM. Robert W. Baird upped their target price on shares of DexCom from $296.00 to $373.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 29th. Raymond James increased their price target on shares of DexCom from $360.00 to $395.00 and gave the company an “outperform” rating in a research report on Tuesday, June 9th. Citigroup reiterated a “buy” rating and set a $485.00 price target (up from $440.00) on shares of DexCom in a research report on Wednesday. Bank of America reiterated a “buy” rating and set a $500.00 price target on shares of DexCom in a research report on Tuesday. Finally, BidaskClub upgraded shares of DexCom from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 22nd. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. DexCom has a consensus rating of “Buy” and a consensus price target of $367.05.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Options Trading – What is a Straddle?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.